Investigation of cancer stem cell marker CXCR4 in gemcitabine-resistant pancreatic cance

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10192
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Nagoya City University
• Principal Investigator: Takeyama Hiromitsu 名古屋市立大学, 大学院医学研究科, 名誉教授 (00216946)
• Co-Investigator(Kenkyū-buntansha): 松尾 洋一 名古屋市立大学, 大学院医学研究科, 准教授 (40381800) ; 森本 守 名古屋市立大学, 大学院医学研究科, 助教 (60722569) ; 佐藤 崇文 名古屋市立大学, 大学院医学研究科, 研究員 (10747257) ; 齊藤 健太 名古屋市立大学, 大学院医学研究科, 助教 (10770240)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 膵癌 / ゲムシタビン耐性 / CXCR4 / CXCR4 antagonist / 新規膵癌治療薬

Outline of Final Research Achievements

Gemcitabine (Gem) is widely used for chemotherapy for pancreatic cancer, but the effect is not fully satisfactory, and the reason is resistance. We succeeded in establishing a Gem-resistant pancreatic cancer cell line and confirmed that the expression of CXCR4, a cancer stem cell marker, is enhanced along with resistance with DNA microarray. We also found that CXCR4 is involved in the proliferation and infiltration of Gem-resistant pancreatic cancer via cancer stromal interaction, which was confirmed to be suppressed by control of CXCR4 signal such as CXCR4 antagonist. Based on the above findings, we found a new finding that control of CXCR4 is a target for novel therapeutic drugs in Gem-resistant pancreatic cancer.

Free Research Field

消化器外科, 肝胆膵外科